Sumitomo Mitsui Trust Group Inc. Has $130.34 Million Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• Sumitomo Mitsui Trust Group boosted its stake in Alnylam to 327,763 shares — roughly $130.34 million — a 4.2% increase that represents about 0.25% of the company.
• Company insiders have been selling recently: CEO Yvonne Greenstreet sold 6,958 shares and EVP Kevin Fitzgerald sold 2,041, with insiders offloaded 38,656 shares (~$12.37M) in the past three months and now owning 1.50% of the stock.
• Analysts maintain a consensus Moderate Buy with an average price target of $472.78, even though Alnylam’s latest quarter missed EPS and revenue estimates despite revenue rising ~85% year‑over‑year and the share price trading near $333.

Sumitomo Mitsui Trust Group Inc. raised its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 4.2% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 327,763 shares of the biopharmaceutical company's stock after acquiring an additional 13,311 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned approximately 0.25% of Alnylam Pharmaceuticals worth $130,335,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its position in Alnylam Pharmaceuticals by 2.0% in the 3rd quarter. Vanguard Group Inc. now owns 13,565,452 shares of the biopharmaceutical company's stock valued at $6,185,846,000 after acquiring an additional 268,313 shares during the period. Capital Research Global Investors increased its position in Alnylam Pharmaceuticals by 0.4% in the 3rd quarter. Capital Research Global Investors now owns 7,222,840 shares of the biopharmaceutical company's stock valued at $3,293,516,000 after acquiring an additional 31,184 shares during the period. Groupama Asset Managment increased its position in Alnylam Pharmaceuticals by 160.4% in the 3rd quarter. Groupama Asset Managment now owns 4,032,082 shares of the biopharmaceutical company's stock valued at $18,610,000 after acquiring an additional 2,483,697 shares during the period. Orbis Allan Gray Ltd increased its position in Alnylam Pharmaceuticals by 29.8% in the 2nd quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company's stock valued at $691,771,000 after acquiring an additional 486,489 shares during the period. Finally, Arrowstreet Capital Limited Partnership increased its position in Alnylam Pharmaceuticals by 698.8% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 1,355,609 shares of the biopharmaceutical company's stock valued at $618,158,000 after acquiring an additional 1,185,909 shares during the period. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 6,958 shares of the firm's stock in a transaction on Friday, February 13th. The shares were sold at an average price of $310.08, for a total value of $2,157,536.64. Following the transaction, the chief executive officer directly owned 85,662 shares of the company's stock, valued at approximately $26,562,072.96. This trade represents a 7.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 2,041 shares of the firm's stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $331.96, for a total transaction of $677,530.36. Following the completion of the transaction, the executive vice president directly owned 21,264 shares in the company, valued at $7,058,797.44. This trade represents a 8.76% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 38,656 shares of company stock valued at $12,370,696. Corporate insiders own 1.50% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have issued reports on the stock. Jefferies Financial Group restated a "hold" rating and issued a $330.00 price target (down from $522.00) on shares of Alnylam Pharmaceuticals in a research report on Monday, March 16th. Leerink Partners decreased their price objective on shares of Alnylam Pharmaceuticals from $370.00 to $351.00 and set a "market perform" rating for the company in a research report on Monday, December 15th. Chardan Capital reiterated a "buy" rating and set a $425.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Wednesday, March 25th. Wall Street Zen cut shares of Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Saturday, March 21st. Finally, Canaccord Genuity Group increased their price objective on shares of Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the stock a "buy" rating in a research report on Tuesday, February 17th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $472.78.

Alnylam Pharmaceuticals Trading Up 3.4%

NASDAQ:ALNY opened at $333.00 on Tuesday. The company has a current ratio of 2.76, a quick ratio of 2.71 and a debt-to-equity ratio of 1.28. The stock has a market capitalization of $44.43 billion, a price-to-earnings ratio of 194.74 and a beta of 0.39. The firm has a fifty day simple moving average of $324.05 and a two-hundred day simple moving average of $389.34. Alnylam Pharmaceuticals, Inc. has a 12 month low of $225.84 and a 12 month high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 EPS for the quarter, missing analysts' consensus estimates of $1.43 by ($0.18). The company had revenue of $1.10 billion during the quarter, compared to analyst estimates of $1.16 billion. Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The company's revenue for the quarter was up 84.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.65) earnings per share. Analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc NASDAQ: ALNY is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.